SAHPRA Approves Groundbreaking HIV Prevention Injection
The South African Health Products Regulatory Authority (SAHPRA) has approved a new HIV prevention injection called Lenacapavir.
Developed by Gilead, the six-monthly injection can be used by adults and teenagers weighing at least 35 kilograms, and must be combined with safer sex practices, such as condom use.
SAHPRA reviewed the medicine in collaboration with the European Medicines Agency to accelerate access to essential treatments.
“The registration of Lenacapavir is a game-changer, given the high infection rate of HIV in South Africa. This product is the most effective HIV prevention measure thus far,”
said SAHPRA’s CEO, Dr Boitumelo Semete-Makokotlela.
Author summary: SAHPRA approved Lenacapavir injection.